contacts
business

Hampleton Partners Advises In Sale Of BaseCase, A Life Sciences Data Visualisation Company, To Certara

BaseCase’s customer engagement platform will enhance Certara’s position as the leading technology-enabled life sciences decision support and consulting organisation.

London, 2nd February 2018 - Hampleton Partners, the international mergers and acquisitions advisory firm for technology companies, has advised BaseCase Management GmbH, a data visualisation software as a service (SaaS) company, headquartered in Berlin, Germany, with offices in New York, on its sale to Princeton, New Jersey-based Certara, the global leader in model-informed drug development and regulatory science.

The healthcare industry is under increasing pressure to demonstrate the value delivered by new medications and devices. BaseCase’s interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians and healthcare providers, or payers and health authorities. This elegant cloud-based solution is ideal for companies seeking to build their own bespoke, branded apps to deliver impactful communication of complex models, analyses, and data. By integrating content creation with sales enablement, it allows users to quickly create and personalize a visual value proposition around a drug or device’s ROI and business case.

Miro Parizek, Hampleton principal partner, says: “BaseCase is now part of a company that is an optimal fit and it can focus on further developing its platform and offering. It has been a pleasure to work with BaseCase Co-founder and CEO Gijs Hubben, PhD, and his team, advising them through this game-changing journey and delivering a highly advantageous result for both BaseCase and Certara.”

Dr. Hubben emphasises: “Hampleton’s team was very experienced and strategic in its approach, constantly hands-on and delivered exactly what it promised from the outset. With a global reach and in-depth understanding of what makes high-technology healthcare businesses special, its team proved informed and creative in everything from initial positioning to final negotiations.”

Jonathan Simnett, Hampleton director and industry expert, adds, “This engagement was a typical challenge in which Hampleton excels, as previously separate sectors in the technology economy converge. Success has been achieved through in-depth understanding of how the healthcare industry is under increasing pressure to demonstrate the value delivered by new medications and devices, combined with experience of M&A in the life sciences sector, customer engagement and sales enablement industries.”

The project was managed by Jonathan Simnett and Anton Røthe. Financial details about the transaction were not disclosed.

 
press contacts

Jane Henry e-mail
+44 789 666 8155



illustration

image for web
original [jpg 42 K]
1292x288 px
business

© 2007